Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00173-0804-09 00173-0804 Pazopanib Hydrochloride Votrient 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, Lck, FMS Oral Oct 19, 2009 Jun 30, 2017 No Longer Used
00173-0804-61 00173-0804 Pazopanib Hydrochloride Votrient 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, Lck, FMS Oral Oct 19, 2009 Nov 30, 2017 No Longer Used
50633-0210-11 50633-0210 Glucarpidase Voraxaze 1000.0 [USP'U]/1 Ancillary Therapy Chemoprotective Antidote Intravenous Apr 1, 2012 In Use
72694-0879-10 72694-0879 Vorasidenib VORANIGO 10.0 mg/1 Chemotherapy IDH Inhibitor IDH1, IDH2 Oral Aug 7, 2024 In Use
72694-0728-40 72694-0728 Vorasidenib VORANIGO 40.0 mg/1 Chemotherapy IDH Inhibitor IDH1, IDH2 Oral Aug 7, 2024 In Use
72482-0100-12 72482-0100 Pacritinib Vonjo 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor JAK2, FLT3 Oral Feb 28, 2022 In Use
63539-0197-90 63539-0197 Dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb 1, 2019 In Use
00069-2299-30 00069-2299 dacomitinib Vizimpro 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 In Use
00069-0197-30 00069-0197 dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 In Use
00069-1198-30 00069-1198 dacomitinib Vizimpro 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 In Use
71225-0120-01 71225-0120 BENDAMUSTINE HYDROCHLORIDE VIVIMUSTA 25.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec 7, 2022 In Use
50419-0393-03 50419-0393 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL Dec 6, 2022 In Use
71777-0392-01 71777-0392 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Nov 26, 2018 In Use
71777-0391-01 71777-0391 LAROTRECTINIB VITRAKVI 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Nov 26, 2018 In Use
50419-0392-01 50419-0392 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL Jul 26, 2019 In Use
50419-0390-01 50419-0390 LAROTRECTINIB VITRAKVI 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Jul 26, 2019 In Use
71777-0390-01 71777-0390 LAROTRECTINIB VITRAKVI 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Nov 26, 2018 In Use
50419-0391-01 50419-0391 LAROTRECTINIB VITRAKVI 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Jul 26, 2019 In Use
69468-0151-10 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Mar 1, 2016 In Use
69468-0151-04 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Mar 1, 2016 In Use
50633-0220-20 50633-0220 Uridine triacetate VISTOGARD 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Jul 31, 2024 In Use
69468-0151-20 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Mar 1, 2016 In Use
50633-0220-04 50633-0220 Uridine triacetate VISTOGARD 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Jul 31, 2024 In Use
55390-0070-01 55390-0070 Vinorelbine Vinorelbine Chemotherapy Antimitotic Agent Vinca Alkaloid Feb 11, 2004 Dec 31, 2012 No Longer Used
00703-4183-91 00703-4183 Vinorelbine Vinorelbine 50.0 mg/5mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Mar 1, 2003 Dec 31, 2012 No Longer Used

Found 11120 results — Export these results